Search results for Hoffmann-La Roche - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Clinical Trials Sponsored by Hoffmann-La Roche

Total 2365 results

NCT04961996

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Conditions: Early Breast Cancer
NCT04546009

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
NCT03193190

Recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Conditions: Pancreatic Adenocarcinoma
NCT05686551

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Conditions: Huntington Disease
NCT05476926

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
NCT05459129

Recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Conditions: Squamous Cell Carcinoma of the Head and Neck
NCT05419388

Recruiting

A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Conditions: Melanoma
NCT05039619

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis

Conditions: Lupus Nephritis
NCT04777331

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Conditions: Parkinsons Disease
NCT04712097

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Conditions: Relapsed or Refractory Follicular Lymphoma
NCT04408638

Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT04285567

Recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04077723

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Conditions: Lymphoma, Non-Hodgkin
NCT05646862

Not yet recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Conditions: Breast Cancer
NCT04431726

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Conditions: Severe Hemophilia A
NCT03677154

Active, not recruiting

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT03559647

Active, not recruiting

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Conditions: Non-Small Cell Lung Cancer (NSCLC)
NCT03194893

Active, not recruiting

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Conditions: Neoplasms
NCT01358877

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Conditions: Breast Cancer
NCT04252339

Completed

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Solid Tumor, Unspecified, Adult
NCT03024996

Completed

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

Conditions: Renal Cell Carcinoma
NCT05704361

Recruiting

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT05503264

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
NCT05377034

Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Conditions: Locally Advanced Hepatocellular Carcinoma
NCT05269004

Recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Conditions: Multiple Sclerosis